Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients. SHINE-RLS (Super High-flux Dialysis Improves Neuro-symptoms and Efficacy in Restless Legs Syndrome) (SHINE-RLS)
Advancing Dialyzer Technology: Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Patients with end-stage kidney disease (ESKD) on regular high-flux hemodialysis (HD) often experience an accumulation of middle-molecule uremic toxins, which are linked to systemic inflammation and troubling symptoms such as restless legs syndrome (RLS), severe itching, and poor sleep quality. While traditional high-flux dialysis efficiently clears small molecules, its ability to remove larger middle-molecule toxins (like α1-microglobulin [α1-MG]) is limited. Current alternatives such as online hemodiafiltration (HDF) have limitations, highlighting the need for new treatment approaches. Super High-Flux Hemodialysis (SHFHD) offers enhanced clearance of these middle molecules while preserving serum albumin levels and maintaining patient safety.
In this study, the investigators evaluate the effectiveness and safety of SHFHD compared with high-flux HD in patients undergoing maintenance HD, focusing on α1-MG removal and its potential effect on RLS. The investigators also explore the multiple diverse effects of SHFHD on the changes of cardiovascular risk factors including bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients.
It is to conduct a randomized, controlled, crossover trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. The investigators will stratify participants by baseline RLS. Participants will receive either SHFHD or high-flux HD for 12 weeks, followed by a 4-week washout and crossover. The study outcome measures are difference in change-from-baseline values of α1-MG reduction ratio, RLS severity (International Restless Legs Scale), albumin levels, clearance of β2-microglobulin, free light chains, inflammatory markers, pruritus scores, and quality of life. Safety will be assessed via albumin maintenance, adverse events, and hemodynamic stability.
This will be the first RCT directly evaluating SHFHD for α1-MG removal and RLS outcomes, addressing critical knowledge gaps and potentially informing new dialysis prescription strategies.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Wan-Chuan Tsai, M.D., Ph.D.
- Telefoonnummer: 1780 886-289667000
- E-mail: mkks618@gmail.com
Studie Locaties
-
-
Banciao Dist.
-
New Taipei City, Banciao Dist., Taiwan, 220
- Far Eastern Memorial Hospital
-
Contact:
- Wan-Chuan Tsai, M.D., Ph.D.
- Telefoonnummer: 1780 886-277281780
- E-mail: mkks618@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Diagnosis of Restless Legs Syndrome according to standard criteria.
- Age ≥ 20 years.
- Maintenance high-flux hemodialysis for ≥ 3 months.
- Stable vascular access (AV fistula or AV graft).
- Adequate dialysis delivery (URR ≥ 65% or Kt/V(daugirdes) ≥ 1.2).
- Sufficient iron stores (serum ferritin ≥ 200 ng/mL, TSAT ≥ 20%).
- Clinically stable condition for the past 4 weeks.
- Able and willing to comply with study protocol
Exclusion Criteria:
- Low-flux HD or temporary catheter use
- Serum albumin < 2.5 g/dL
- Recent hospitalization (within 4 weeks)
- Scheduled kidney transplantation
- Active malignancy or infection
- Pregnancy
- Any condition impairing protocol adherence
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Enkel
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Super High-Flux HD
Receives 12 weeks of Super High-Flux HD (Elisio™-HX)
|
Participants receive hemodialysis using a Type V super high-flux dialyzer (such as Elisio™-HX or Theranova) for 12 weeks to assess the clearance of middle-molecule uremic toxins and its effect on RLS symptoms.
|
|
Geen tussenkomst: High-Flux HD
Receives 12 weeks of High-Flux HD as usual care
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in α1-microglobulin (α1-MG) Reduction Ratio
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio of α1-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit.
The primary outcome is the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in International Restless Legs Scale (IRLS) Score
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
IRLS score assesses the severity of Restless Legs Syndrome (ranging from 0 to 40, where higher scores indicate greater severity).
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum Albumin Level
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Monitored to evaluate nutritional safety and albumin preservation during Super High-Flux HD compared to High-Flux HD.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses sleep quality.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in 5-D Itch Scale Score
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses pruritus severity.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in health-related quality of life (EQ-5D-5L) Score
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses quality of life.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in β2-microglobulin [β2-MG] Reduction ratio
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio of β2-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Kappa Free Light Chains Reduction ratio
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Lambda Free Light Chains Reduction ratio
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum interleukin-6 (IL-6) Level
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum High-sensitivity C-reactive Protein (hs-CRP) Level
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum Indoxyl Sulfate Level
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum P-cresol Sulfate Level
Tijdsspanne: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Pathologische processen
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Chronische ziekte
- Ziekte attributen
- Slaap-waakstoornissen
- Nierinsufficiëntie
- Slaapstoornissen, intrinsiek
- Dyssomnieën
- Parasomnieën
- Pathologische aandoeningen, tekenen en symptomen
- Nierfalen, chronisch
- Nierinsufficiëntie, chronisch
- Rusteloze benen syndroom
Andere studie-ID-nummers
Andere studie-ID-nummers
- FEMH-IRB-TSAI2025
- FEMH-IIT-2026-01 (Ander subsidie-/financieringsnummer: Far Eastern Memorial Hospital)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .